Andere Sprachen BioLineRx Ltd. Nasdaq

Aktien

A2PNW3

US09071M2052

BLRX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 07.06.2024			% 5 Tage	% 1. Jan.
0.6576 ^USD	-5.59%		-11.80%	-58.11%

30.05.	BioLineRx Ltd. gibt eine Vereinbarung mit dem St. Jude Children's Research Hospital, Inc. über eine klinische Studie zur Untersuchung von Motixafortide zur Mobilisierung von CD34+ hämatopoetischen Stammzellen für gentherapeutische Anwendungen bei Sichelzellanämie bekannt	CI
28.05.	Transcript : BioLineRx Ltd., Q1 2024 Earnings Call, May 28, 2024

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapy Applications in Sickle Cell Disease	31.05.
BioLineRx Ltd Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications in Sickle Cell Disease	30.05.
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates	29.05.
BioLineRx : Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates	28.05.
BioLineRx Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	28.05.
BioLineRx Ltd. announced that it has received $26 million in funding from Kreos Capital Management (UK) Limited	28.05.
BioLineRx Ltd. Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer at American Society of Clinical Oncology	24.05.
BioLineRx to Report First Quarter 2024 Results on May 28, 2024	22.05.
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification	20.05.
BioLineRx : Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024	06.05.
BioLineRx : Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	17.04.
BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	17.04.
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	10.04.
BioLineRx Ltd. Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	10.04.
BioLineRx Announces $6 Million Registered Direct Offering	02.04.
BioLineRx Shares Fall After $6 Million Registered Direct Offering	01.04.
BioLineRx : Form 20-F/A (Amendment No. 1	28.03.
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates	27.03.
BioLineRx : Annual Report on Form 20-F FOR 2023	26.03.
BioLineRx : Report of Periodic or Interim Report	26.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen BioLineRx Ltd. Nasdaq

Aktien

A2PNW3

US09071M2052

BLRX

Andere Sprachen

Filter